

原著論文

*は他教室への協力 †Contributed equally

2025 年

1. Furukawa H, Iwasaki T, Kawaguchi K, Sonoda H, Kohashi K, Yamamoto H, Nakashima Y, Oda Y.
Reduced 5-hydroxymethylcytosine due to TET2 downregulation is associated with chondrosarcoma progression.
Sci Rep. 2025 Nov;15(1):41854
2. Hamada H, Kohashi K, Iwasaki T, Hashisako M, Hino Y, Fukuhara M, Kamouchi A, Kawakubo N, Tajiri T, Oda Y.
Adjunctive diagnostic tool for histopathological classification of congenital mesoblastic nephroma based in molecular genetic findings.
J Cancer Res Clin Oncol. 2025 Feb;151(2):69
3. Iwasaki T, Masunaga M, Tomonaga T, Masumoto Y, Akiyama Y, Oda Y.
Comprehensive analysis of N6-Methyladenosine (m6A) RNA methylation regulators in soft tissue leiomyosarcoma.
Lab Invest. 2025 Nov;105(11):104221
4. Katayama Y, Iwasaki T, Yamamoto T, Shimada N, Nakashima M, Toya M, Narutomi F, Tomonaga T, Kato K, Oda Y.
Loss of SMARCA4 induces sarcomatogenesis through epithelial-mesenchymal transition in ovarian carcinosarcoma.
Cancer Sci. 2025 Mar;116(3):835-845
5. Kawaguchi K, Kohashi K, Iwasaki T, Mori T, Furukawa H, Sato C, Sonoda H, Shiraishi S, Endo M, Nakashima Y, Oda Y.
Nuclear morphological atypia in biopsy accurately reflects the prognosis of myxoid liposarcoma.
Virchows Arch. 2025 Feb;486(2):373-380
6. Kiyozawa D, Fukuchi G, Miyamoto T, Umekita S, Takamatsu D, Kohashi K, Eto M, Oda Y.
Comprehensive mRNA expressional analysis of SMARCB1-deficient renal cell carcinoma in patients without hemoglobinopathies.
Genes Chromosomes Cancer. 2025 Jul;64(8):e70069
7. Takahashi A†, Kiyozawa D†, Miyauchi T†, Mirocha J, Kevin Ren YM, Doi T, Grace Choung HY, Lin MY, Hou J, Masaki T, Oda Y, Haas M, Nast CC, Yamashita M.
Temporal and demographic trends in biopsy-proven kidney disease diagnoses in the Southwestern United States, 1993-2022.
Kidney Med. 2025 Oct;7(12):101131
8. Noguchi S, Yamamoto T, Nakanishi Y, Matsumoto T, Shimada Y, Shindo K, Nakata K, Fujita N, Ishigami K, Nakamura M, Oda Y.
Prognostic significance of desmoplastic reaction classification and its association with stromal biomarkers in pancreatic ductal adenocarcinoma.
Mod Pathol. 2025 Oct;38(10):100865
9. Shimada Y, Yamamoto T, Shindo K, Nakanishi Y, Matsumoto T, Noguchi S, Aishima S, Nakamura M, Oda Y.
Clinicopathologic and genomic features of gastric-type intraductal papillary neoplasm of the bile duct: potential role of STK11 in malignant progression.
Am J Surg Pathol. 2025 Oct;49(10):1004-1014
10. Sonoda H, Iwasaki T, Ishihara S, Mori T, Nakashima Y, Oda Y.
Impact of tertiary lymphoid structure on prognosis and tumor microenvironment in undifferentiated pleomorphic sarcoma.
Cancer Sci. 2025 May;116(5):1464-1473
11. Taniguchi Y, Kiyozawa D, Kohashi K, Kawatoko S, Yamamoto T, Torisu T, Yoshizumi T, Nakamura M, Kitazono T, Oda Y.
Volume of hepatoid component and intratumor M2 macrophages predict prognosis in patients with hepatoid adenocarcinoma of the stomach.
Gastric Cancer. 2025 Jan;28(1):41-50
12. Umekita S, Kiyozawa D, Honma H, Kohashi K, Taniguchi Y, Kawatoko S, Sasaki T, Ihara E, Oki E, Nakamura M, Ogawa Y, Oda Y.
Clinicopathological significance of JAK2, STAT3, and STAT4 expression in patients with gastric solid-type poorly differentiated adenocarcinoma: a retrospective study.
Gastric Cancer. 2025 May;28(3):455-464

13. *Aoyagi T†, Goya T†, Imoto K, Azuma Y, Hioki T, Kohjima M, Tanaka M, Oda Y, Ogawa Y.
Two types of regenerative cell populations appear in acute liver injury.
Stem Cell Reports. 2025 Jun;20(6):102503
14. *Asanoma K, Yahata H, Kodama K, Okugawa K, Yasunaga M, Onoyama I, Yagi H, Maenohara S, Hachisuga K, Isoda T, Shimokawa M, Ishigami K, Oda Y, Kato K.
Sentinel lymph node detection using SPECT and gamma probe in low-risk endometrial cancer: efficacy and factors associated with detection failure.
Asian J Endosc Surg. 2025 Jan-Dec;18(1):e70015
15. *Funauchi Y, Tsukushi S, Hiraga H, Sakamoto A, Kunisada T, Nagano A, Hiraoka K, Kikuta K, Yonemoto T, Ae K, Kawai A, Endo M, Sano Y, Machida R, Sekita T, Fukuda H, Oda Y, Ozaki T, Tanaka K; JCOG Bone Soft Tissue Tumor Study Group.
Study protocol: randomized phase III trial of neo-adjuvant and adjuvant chemotherapy vs. immediate surgery and adjuvant chemotherapy for localized soft tissue sarcoma: Japan Clinical Oncology Group study JCOG2102 (NACLESS).
Jpn J Clin Oncol. 2025 Mar;55(3):297-303
16. *Hachisuga K, Kawakami M, Tomonobe H, Maenohara S, Kodama K, Yagi H, Yasunaga M, Onoyama I, Asanoma K, Yahata H, Oda Y, Kato K.
Low-grade endometrial cancer with abnormal p53 expression as a separate clinical entity: insights from RNA sequencing and immunohistochemistry.
Diagnostics (Basel). 2025 Mar;15(6):671
17. *Hashinokuchi A, Haratake N, Ono Y, Tomonaga T, Bassi G, Matsudo K, Kinoshita F, Matsubara T, Kohno M, Takenaka T, Oda Y, Yoshizumi T.
Clinical and biological impact of SNAT7 in lung adenocarcinoma: implications for prognosis and treatment.
Int J Clin Oncol. 2025 Oct;30(10):1972-1981
18. *Hashinokuchi A, Kinoshita F, Iimori M, Kosai K, Ono Y, Tomonaga T, Giacomo B, Matsudo K, Nagano T, Akamine T, Kohno M, Takenaka T, Oda Y, Yoshizumi T.
DNA polymerase delta 2 activates cell cycle in lung adenocarcinoma, leading to high malignancy and poor prognosis.
Ann Surg Oncol. 2025 Jun;32(6):4487-4496
19. *Hioki T†, Imoto K†, Goya T, Azuma Y, Horiuchi A, Aoyagi T, Takahashi M, Oda Y, Kato M, Kohjima M, Tanaka M, Ogawa Y.
Clinicopathological features of steroid-refractory immune-mediated hepatotoxicity induced by immune checkpoint inhibitors.
BMC Gastroenterol. 2025 Dec;26(1):49
20. *Ibusuki R, Iwama E, Shimauchi A, Kawano H, Mizusaki S, Nakamura S, Miyazaki Y, Inutsuka Y, Hashisako M, Harada T, Tsuchiya-Kawano Y, Tsutsumi H, Nakanishi T, Nakagaki N, Koga Y, Kimura S, Mashimoto S, Shibahara D, Otsubo K, Yoneshima Y, Tanaka K, Oda Y, Okamoto I.
IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non-small cell lung cancer.
Mol Cancer. 2025 Oct;24(1):272
21. *Ichimiya S, Ahn SS†, Dixon MS†, O'Sullivan JP, DeVine LC, Chen A, Yamamoto T, Oda Y, Nakamura M, Chio IIC.
Dual role of NRF2 in pancreatic precursor lesions.
Cancer Res Commun. 2025 Jun;5(6):945-959
22. *Imabayashi K, Yada Y, Kawata K, Yoshimura M, Iwasaki T, Baba A, Harada A, Akashi K, Niuro H, Baba Y.
Critical roles of chronic BCR signaling in the differentiation of anergic B cells into age-associated B cells in aging and autoimmunity.
Sci Adv. 2025 Apr;11(16):eadt8199
23. *Inomata Y, Kodama K, Maenohara S, Yagi H, Yasunaga M, Onoyama I, Asanoma K, Yahata H, Oda Y, Kato K.
Retrospective analysis of treatment and prognosis for clear cell carcinoma of the uterine cervix: 15-year experience at a single institution.
J Obstet Gynaecol Res. 2025 Apr;51(4):e16300
24. *Ito T, Tanaka Y, Ogata D, Nishida H, Shiomi T, Tanaka R, Kawaguchi A, Miyashita A, Fukushima S, Shojiguchi N, Goto H, Togawa Y, Kiyohara T, Oda Y, Nakahara T.
A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan.
Sci Rep. 2025 Jan;15(1):409

25. *Jin Y, Arimura H, Iwasaki T, Kodama T, Yamamoto N, Cui Y, Oda Y.
Multiscale-fusion models with genomic, topological and pathomic features to predict response to radiation therapy for non-small cell lung cancer patients.
Lab Invest. 2025 Oct;105(10):104204
26. *Katayama N, Ohuchida K, Son K, Tsutsumi C, Mochida Y, Noguchi S, Iwamoto C, Torata N, Horioka K, Shindo K, Mizuuchi Y, Ikenaga N, Nakata K, Oda Y, Nakamura M.
Tumor infiltration of inactive CD8 + T cells was associated with poor prognosis in Gastric Cancer.
Gastric Cancer. 2025 Mar;28(2):211-227
27. *Kimura R, Miyasaka Y, Noma K, Taniguchi T, Nakafusa T, Tomosugi T, Ideno N, Mori Y, Nakata K, Ohtsuka T, Yamamoto T, Oda Y, Nakamura M.
Risk factors for early recurrence of resectable pancreatic cancer.
Anticancer Res. 2025 Oct;45(10):4441-4452
28. *Koike A, Tsubouchi K, Nakamura S, Takano T, Hashisako M, Hino T, Yabuuchi H, Okamoto I.
Diagnostic yield and safety of transbronchial lung cryobiopsy using 1.7-mm probes in interstitial lung disease.
J Thorac Dis. 2025 Jun;17(6):3962-3970
29. *Kuma Y, Kido-Nakahara M, Kuba-Fuyuno Y, Matsumoto T, Oda Y, Eto M, Nakahara T.
Enfortumab vedotin-related skin toxicities: insights from clinical and histopathological analysis.
J Dermatol. 2025 Oct;52(10):1584-1588
30. *Leong M†, Lee CYJ†, Yamashita M, Kiyozawa D, Han MH, Nast CC.
Punctate podocyte IgG staining does not differentiate primary from secondary minimal change disease.
Glomerular Dis. 2025 Jun;5(1):316-327
31. *Maezono A, Oishi E, Sasaki T, Takase S, Sakata S, Hata J, Oda Y, Kitazono T, Abe K, Ninomiya T.
Electrocardiographic p-wave indices and onset of atrial fibrillation and histological fibrosis in a general Japanese population: a prospective cohort analysis of the Hisayama Study.
Eur Heart J Open. 2025 Sep;5(6):oeaf126
32. *Marumoto H, Sasaki T, Oishi E, Sakata S, Shibata M, Furuta Y, Hata J, Oda Y, Kitazono T, Tsuboi N, Yokoo T, Ninomiya T.
Nephrosclerosis-related histopathological findings by cortical region from a Japanese community-based study.
Kidney Med. 2025 Dec;8(2):101194
33. *Matsudo K, Takada K, Hashinokuchi A, Nagano T, Kinoshita F, Akamine T, Kohno M, Takenaka T, Shimokawa M, Oda Y, Yoshizumi T.
Significance of tumor microvasculature in the tumor microenvironment in adenocarcinoma with EGFR common mutations.
Ann Surg Oncol. 2025 Apr;32(4):3031-3039
34. *Matsudo K, Takada K, Hashinokuchi A, Nagano T, Kinoshita F, Akamine T, Kohno M, Takenaka T, Shimokawa M, Oda Y, Yoshizumi T.
CD155 expression and co-expression with PD-L1 are not associated with poor prognosis in patients with stage II and III lung adenocarcinoma undergoing surgical resection.
Int J Clin Oncol. 2025 Jul;30(7):1319-1330
35. *Mochida Y, Ohuchida K, Zhang B, Yamada Y, Tsutsumi C, Kubo A, Oyama K, Shinkawa T, Iwamoto C, Torata N, Abe T, Ideno N, Ikenaga N, Nakata K, Oda Y, Nakamura M.
Identification of cold tumor induction-related markers in pancreatic cancer and the clinical implication of PCDH7.
J Cancer Res Clin Oncol. 2025 Jan;151(2):45
36. *Nagano T†, Takada K†, Hashinokuchi A, Matsudo K, Kinoshita F, Akamine T, Kohno M, Shimokawa M, Takenaka T, Oda Y, Yoshizumi T.
Clinical significance of CD155 expression in surgically resected lung squamous cell carcinoma.
Int J Clin Oncol. 2025 Jan;30(1):62-71
37. *Oyama R, Nabeshima A, Endo M, Novikov A, Fujiwara T, Phelip C, Yokoyama N, Oda Y, Caroff M, Matsumoto Y, Kerzerho J, Nakashima Y.
A detoxified TLR4 agonist inhibits tumour growth and lung metastasis of osteosarcoma by promoting CD8+ cytotoxic lymphocyte infiltration.
BJC Rep. 2025 Jan;3(1):5
38. *Schwarz A, Arimura H, Cui Y, Shimabukuro S, Lin Q, Jin Y, Kobayashi S, Matsumoto T, Shiota M, Eto M, Oda Y.
Fractal dimensions for tumour-related cell types of prostate cancer on histopathology images using multiple-threshold box counting algorithm.
Biophys Physicobiol. 2025 Oct;22(4):e220026

39. *Shibayama Y, Arimura H, Takayama Y, Kinoshita F, Takamatsu D, Nishie A, Kobayashi S, Matsumoto T, Shiota M, Eto M, Oda Y, Ishigami K.
Explainable radiomics based on association of histopathological cell density and multiparametric MR radiomic features for high-risk stratification of prostate cancer patients.
MAGMA. 2025 Oct;38(5):803-815
40. *Shindo K, Ohuchida K, Nagasue T, Ogino H, Horioka K, Moriyama T, Nagayoshi K, Mizuuchi Y, Ikenaga N, Nakata K, Oda Y, Nakamura M.
Efficacy of laparoscopic and endoscopic cooperative surgery compared to endoscopic resection for duodenal tumor treatment.
Asian J Endosc Surg. 2025 Jan-Dec;18(1):e70130
41. *Suzuki M, Koga Y, Kawasaki T, Ueda T, Yamamoto S, Goto H, Kishimoto J, Ishida E, Todaka K, Sonoda KH, Oda Y, Koji Y, Sakai Y, Ohga S.
Access program for unapproved and off-label drug use in pediatric BRAF V600E-Mutated brain tumors in Japan.
Pediatr Blood Cancer. 2025 Mar;72(3):e31510
42. *Taira J, Kawatoko K, Takamatsu D, Shiota M, Ogata H, Hata J, Oishi E, Sakata S, Furuta Y, Shibata M, Ohara T, Oda Y, Eto M, Ninomiya T.
Secular trends in the prevalence of total and latent prostate cancer over half a century according to consecutive autopsy cases in a Japanese community: The Hisayama Study.
Eur Urol Open Sci. 2025 Jun;78:9-15
43. *Tanaka Y, Hu Q, Kawazoe T, Tajiri H, Nakanishi R, Zaitzu Y, Nakashima Y, Ota M, Oki E, Oda Y, Yoshizumi T.
The clinical significance of signal regulatory protein alpha expression in the immune environment of gastric cancer.
Int J Clin Oncol. 2025 Feb;30(2):330-339
44. *Tanaka Y, Oki E, Nakanishi R, Kawazoe T, Kudo K, Zaitzu Y, Hisamatsu Y, Ando K, Oda Y, Yoshizumi T.
Polo-Like Kinase 1 expression in colorectal cancer: association with RAS mutations.
Cancer Sci. 2025 Jul;116(7):2032-2039
45. *Toshida K, Itoh S, Nakayama Y, Yugawa K, Ishikawa T, Tsutsui Y, Tomiyama T, Iseda N, Fujiyoshi S, Motomura T, Toshima T, Iwasaki T, Oda Y, Yoshizumi T.
Expression of signal regulatory protein alpha in tumor cells is the key factor in intrahepatic cholangiocarcinoma.
Ann Surg Oncol. 2025 Oct;32(10):8037-8045
46. *Toshida K, Itoh S, Tanaka Y, Toshima T, Yoshiya S, Izumi T, Iseda N, Tsutsui Y, Nakayama Y, Ishikawa T, Ninomiya M, Iwasaki T, Oda Y, Yoshizumi T.
Differences in tumor-infiltrating lymphocyte counts in the peritumoral area in patients undergoing hepatic resection after lenvatinib and atezolizumab plus bevacizumab therapy for hepatocellular carcinoma.
Cancer Med. 2025 Apr;14(8):e70445
47. *Tsutsumi C, Ohuchida K, Imamura M, Tan B, Shimada Y, Son K, Kosai T, Katayama N, Mochida Y, Hayashida S, Iwamoto C, Torata N, Horioka K, Shindo K, Mizuuchi Y, Ikenaga N, Nakata K, Oda Y, Nakamura M.
Prognostic nutrition index reveals LAG3 in cytotoxic CD8+ T cells and MHC class II in gastric cancer cells.
Cancer Immunol Immunother. 2025 Apr;74(6):176
48. *Tsutsumi C, Ohuchida K, Son K, Zhang B, Shimada Y, Imamura M, Katayama N, Kubo A, Higashijima N, Iwamoto C, Torata N, Mizuuchi Y, Ikenaga N, Nakata K, Onishi H, Oda Y, Nakamura M.
uPAR expression in M-MDSCs under high LDHA activity in pancreatic ductal adenocarcinoma.
Sci Rep. 2025 Nov;16(1):398
49. *Tsutsumi C, Ohuchida K, Yamada Y, Shimada Y, Imamura M, Son K, Mochida Y, Katayama N, Iwamoto C, Torata N, Horioka K, Shindo K, Mizuuchi Y, Ikenaga N, Nakata K, Onishi H, Oda Y, Nakamura M.
Claudin18.2-positive gastric cancer-specific changes in neoadjuvant chemotherapy-driven immunosuppressive tumor microenvironment.
Br J Cancer. 2025 May;132(9):793-804
50. *Yamashita M†, Piaseczna N†, Takahashi A, Kiyozawa D, Tatsumoto N, Kaneko S, Zurek N, Gertych A.
AI-driven glomerular morphology quantification: a novel pipeline for assessing basement membrane thickness and podocyte foot process effacement in kidney diseases.
Comput Methods Programs Biomed. 2025 Aug;268:108842

51. *Yokomoto-Umakoshi M†, Fujita M†, Umakoshi H†, Ogasawara T, Iwahashi N, Nakatani K, Kaneko H, Fukumoto T, Nakao H, Haji S, Kawamura N, Shimma S, Seki M, Suzuki Y, Izumi Y, Oda Y, Eto M, Ogawa S, Bamba T, Ogawa Y.
Multiomics analysis unveils the cellular ecosystem with clinical relevance in aldosterone-producing adenomas with KCNJ5 mutations.
Proc Natl Acad Sci U S A. 2025 Mar;122(9):e2421489122
52. *Yoshihiro T, Yamaguchi K, Ariyama H, Koreishi S, Uehara K, Ohmura H, Ito M, Tsuchihashi K, Isobe T, Shindo K, Ohuchida K, Nakamura M, Nagao Y, Oda Y, Akashi K, Baba E.
Elucidation of the mechanism of carcinogenic transformation of human gastric epithelial cells in atrophic gastritis.
Biochim Biophys Acta Mol Basis Dis. 2025 Aug;1871(6):167843
53. *Zhang J, Mizuuchi Y, Ohuchida K, Hisano K, Shimada Y, Katayama N, Tsutsumi C, Tan BC, Nagayoshi K, Tamura K, Fujimoto T, Ikenaga N, Nakata K, Oda Y, Nakamura M.
Exploring the tumor microenvironment of colorectal cancer patients post renal transplantation by single-cell analysis.
Cancer Sci. 2025 Feb;116(2):500-512
54. 並河真美、相島慎一、野上美和子、仲正喜、山本猛雄、長友周三郎、藤森尚、仲田興平、中村雅史、小田義直
膵上皮内癌の細胞診
日本臨床細胞学会九州連合会雑誌. 2025 Jul;56:21-36